Showing 1721-1730 of 2314 results for "".
- Dompé Receives FDA Approval of Oxervate, the First Drug for Neurotrophic Keratitishttps://modernod.com/news/dompe-receives-fda-approval-of-oxervate-a-first-in-class-treatment-of-neurotrophic-keratitis/2479916/The FDA has approved the first drug to treat neurotrophic keratitis, a rare and progressive eye disease that can lead to corneal scarring and vision loss. Oxervate (cenegermin-bkbj ophthalmic solution), which is manufactured by Italian pharmaceutical company Dompé, is based on cenegermin-b
- Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Publishedhttps://modernod.com/news/scientific-data-for-novel-adeno-associated-virus-gene-therapy-in-rhodopsin-mediated-autosomal-dominant-retinitis-pigmentosa-published/2479920/Ophthotech announced that scientists at the University of Pennsylvania (Penn) and University of Florida published proof-of-concept study results on an adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-a
- Regeneron Faces Delay to FDA Approval of 12-Week Dosing Schedule for Eylea in Wet AMDhttps://modernod.com/news/regeneron-faces-delay-to-fda-approval-of-12-week-dosing-schedule-for-eylea-in-wet-amd/2479946/Regeneron announced that the FDA issued a complete response letter regarding a filing seeking approval of a 12-week dosing schedule for »Eylea (aflibercept) in patients wit
- Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 Trial for Dry Eye Disease Treatmenthttps://modernod.com/news/kala-pharmaceuticals-announces-dosing-of-first-patient-in-phase-3-stride-3-trial-of-kpi-121-0-25-in-patients-with-dry-eye-disease/2479973/Kala Pharmaceuticals announced that the first patient has been dosed in STRIDE 3 (Short Term Relief In Dry Eye), its phase 3 trial of KPI-121 0.25% for the short-term treatment of dry eye disease. “We are pleased to initiate the STRIDE 3 trial of KPI-121 0.25%. If approved, KPI-121 0.25% c
- Patients With Down Syndrome May Have Keratoconus-Like Corneashttps://modernod.com/news/patients-with-down-syndrome-may-have-keratoconus-like-corneas/2480022/Over 70% of people with Down syndrome (DS) – many more than previously thought – may have corneas similar in morphology to the corneas of people with keratoconus, a new study reports. People with DS have thinner and stee
- Bausch + Lomb Launches Lumify, the First OTC Redness Relieving Eye Drop With Low-Dose Brimonidinehttps://modernod.com/news/bausch-lomb-launches-lumify-the-first-otc-redness-relieving-eye-drop-with-low-dose-brimonidine/2480169/Bausch + Lomb announced the launch of Lumify (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness. “With the availability of Lumify, consumers now have an in
- Smoking Doubles Risk of Major Eye Diseases, Global Study Findshttps://modernod.com/news/smoking-doubles-risk-of-major-eye-diseases-global-study-finds/2486608/Key Takeaways
- New Study Shows Foundation AI Models Closing the Gap With Doctors—But Multimodal Challenges Remainhttps://modernod.com/news/new-study-shows-foundation-ai-models-closing-the-gap-with-doctorsbut-multimodal-challenges-remain/2485340/A new cross-sectional study published in JAMA Ophthalmology examines how current foundation artificial intelligence (AI) models perform on ophthalmology exam questions compared with human physicians. The data reveal notable progress on text-based tasks but
- Valitor Presents Preclinical Datasets on the Potential of its Anti-VEGF Therapy Dosed Twice Yearly for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-datasets-on-the-potential-of-its-anti-vegf-therapy-dosed-twice-yearly-for-wet-amd/2482790/Valitor announced data from VLTR-559, its long-acting anti-VEGF biologic in development for its wet age-related macular degeneration (AMD) treatment, and its multivalent polymer (MVP) technology platform, were presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annua
- FDA Priority Review Accepted for Eylea HD for Both the Treatment of RVO and for Monthly Dosing in Approved Indicationshttps://modernod.com/news/fda-priority-review-accepted-for-eylea-hd-for-both-the-treatment-of-rvo-and-for-monthly-dosing-in-approved-indications/2482741/Regeneron announced that the FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) Injection 8 mg. The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion (RVO